Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941945 | 0.87 | GRM2 (0.44) | GRM2ADRB3GPR183ACHEMAPT | |
| SCHEMBL4945422 | 0.87 | GRM2 (0.43) | GRM2ADRB3GPR183ACHEACLY | |
| SCHEMBL11654170 | 0.81 | GRM2 (0.44) | GRM2ADRB3GPR183ACHEMAPT | |
| SCHEMBL11027295 | 0.74 | GRM2 (0.50) | GRM2ADRB3GPR183ACHEMAPT | |
| SCHEMBL11659608 | 0.74 | GRM2 (0.41) | GRM2ADRB3GPR183ACHE | |
| SCHEMBL11708448 | 0.74 | MAPT (0.34) | GRM2MAPT | |
| SCHEMBL11708654 | 0.74 | NPC1 (0.38) | GRM2ADRB3GPR183MAPT | |
| SCHEMBL11707808 | 0.72 | LMNA (0.35) | GRM2MAPT | |
| SCHEMBL11654377 | 0.70 | GRM2 (0.50) | GRM2ADRB3GPR183ACHEMAPT | |
| SCHEMBL22804010 | 0.69 | GRM2 (0.52) | GRM2ADRB3GPR183MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312286-A1 | Indanone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-12-18 | — | — | US | disclosed |
| EP-1773792-A1 | INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006015158-A1 | INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312286-A1 | Indanone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRIK2, GRM1 | GRM2 1/4885ADRB3 708/4885GPR183 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.